Vaccine for Celiac Disease is under clinical development by Vactech and currently in Phase I for Celiac Disease. According to GlobalData, Phase I drugs for Celiac Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Vaccine for Celiac Disease LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vaccine for Celiac Disease overview

Vaccine is under development for the treatment and prevention of celiac disease. It consists of virus like particles of enterovirus and it is developed based on the IMVAC technology.

Vactech overview

Vactech is a company that develops and licenses vaccines and novel technologies for vaccines and diagnostics with a pipeline of early stage product candidates focused on type 1 diabetes, celiac disease, asthma and allergy and diagnostics. The company is headquartered in Tampere, Pirkanmaa, Finland.

For a complete picture of Vaccine for Celiac Disease’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.